KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $2.5 billion.

  • Halozyme Therapeutics' Total Liabilities rose 4570.65% to $2.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.5 billion, marking a year-over-year increase of 4570.65%. This contributed to the annual value of $2.5 billion for FY2025, which is 4570.65% up from last year.
  • As of Q4 2025, Halozyme Therapeutics' Total Liabilities stood at $2.5 billion, which was up 4570.65% from $1.7 billion recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Total Liabilities registered a high of $2.5 billion during Q4 2025, and its lowest value of $899.0 million during Q1 2021.
  • Moreover, its 5-year median value for Total Liabilities was $1.7 billion (2023), whereas its average is $1.5 billion.
  • As far as peak fluctuations go, Halozyme Therapeutics' Total Liabilities surged by 11501.47% in 2021, and later crashed by 701.94% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Total Liabilities (Quarter) stood at $907.5 million in 2021, then soared by 84.22% to $1.7 billion in 2022, then decreased by 1.33% to $1.6 billion in 2023, then increased by 3.04% to $1.7 billion in 2024, then skyrocketed by 45.71% to $2.5 billion in 2025.
  • Its Total Liabilities stands at $2.5 billion for Q4 2025, versus $1.7 billion for Q3 2025 and $1.7 billion for Q2 2025.